Rezera, a Phase 3-ready biotech developing oral NLRP3 inhibitors for inflammatory diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Rezera is developing oral inhibitors of NLRP3, the upstream driver of sterile ...read more
Sensing4D AI, which provides AI-powered 3D vision, reconstruction, and digital twin solutions, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. Sensing4D AI provides AI-powered 3D vision solutions to enterprise clients ...read more
Africa-linked IPOs are having a strong year. Seven companies with significant African operations have raised at least $100 million via IPOs so far this year, totaling $2.6 billion in proceeds, more than each of the past five years. The pipeline is...read more
Inflammatory diseases biotech Rezera files for a $100 million IPO
Rezera, a Phase 3-ready biotech developing oral NLRP3 inhibitors for inflammatory diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Rezera is developing oral inhibitors of NLRP3, the upstream driver of sterile ...read more
China-based AI vision solutions provider Sensing4D AI files for a $35 million US IPO
Sensing4D AI, which provides AI-powered 3D vision, reconstruction, and digital twin solutions, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. Sensing4D AI provides AI-powered 3D vision solutions to enterprise clients ...read more
Africa-linked IPOs pick up steam in 2026
Africa-linked IPOs are having a strong year. Seven companies with significant African operations have raised at least $100 million via IPOs so far this year, totaling $2.6 billion in proceeds, more than each of the past five years. The pipeline is...read more